Japan’s medical insurance system introduced a new category titled “C150.” It makes a wider range of people with diabetes eligible to receive reimbursement for the G6 continuous glucose monitor (CGM) in Japan.
Dexcom develops and manufactures the current-generation G6 CGM. It offers the next-generation Dexcom G7 CGM in the UK, Ireland, Germany, Austria and Hong Kong. U.S. approval could come soon, too. Terumo markets the G6 in Japan.
Get the full story at our sister site, Drug Delivery Business News.